HOPE & HOPE Too trials

Introduction

Diabetes subgroup:

Primary outcomes:

• cardiovascular death, myocardial infarction, stroke, heart failure, end-stage renal disease

Results:

• high risk patients given
  • 10 mg of ramipril/day had lower incidence of cardiovascular events
  • 1.25 mg of rampril/day of no benefit

Vitamin E subgroup:

Vitamin E 400 IU/day

mean follow-up of 7 years

Results:

• no differences in beween vit E & placebo in:
  • cancer incidence, cancer deaths
  • combined endpoint of myocardial infarction, stroke, cardiovascular death (21.5% vs 20.6%)
• higher risk of heart failure with vit E vs placebo (13.5% vs 12.1%)

More general terms

• clinical trial

Additional terms

• Heart Outcomes Prevention Evaluation (HOPE)